Key Takeaways
- Eckert & Ziegler collaborates with Telix Pharmaceuticals to produce Ac-225 using innovative cyclotron technology.
- The agreement includes milestone payments of up to €20 million.
- This partnership aims to meet the rising demand for Ac-225 in cancer therapies.
Eckert & Ziegler SE (EZAG) has entered a collaboration and license agreement with Telix Pharmaceuticals Limited, an Australian biopharmaceutical company, to advance the production of Actinium-225 (Ac-225). This agreement leverages Eckert & Ziegler’s cyclotron-based production technology to address the global demand for this highly sought-after isotope used in cancer treatments. As part of the deal, Eckert & Ziegler will receive up to €20 million in milestone payments from Telix within two years.
The partnership marks a significant milestone in Eckert & Ziegler’s strategy to establish itself as a leading supplier of Ac-225 for the radiopharmaceutical industry. By 2025, the company plans to deliver Ac-225 in GMP quality at increased volumes, supporting the growing need for this isotope in innovative cancer therapies.
Rising Demand for Ac-225 in Radiopharmaceuticals
Ac-225-based radiopharmaceuticals are currently under clinical investigation for several cancers, including prostate cancer, colorectal cancer, and leukemia. Promising results from ongoing trials have heightened interest in Ac-225, which works by delivering targeted radiation to cancer cells while minimizing damage to healthy tissue.
Despite its potential, the availability of Ac-225 remains a challenge due to complex production processes. This collaboration with Telix represents a pivotal step toward ensuring a consistent and scalable supply of Ac-225 to meet the projected increase in demand over the next decade.
Eckert & Ziegler’s cyclotron technology offers a groundbreaking approach to producing Ac-225 in larger quantities. This innovation not only addresses current supply constraints but also positions Eckert & Ziegler as a key player in the radiopharmaceutical market.
Strategic Benefits for Eckert & Ziegler and Telix
For Eckert & Ziegler, the partnership enhances its capability to deliver isotopes at scale, consolidating its reputation as a reliable supplier in the radiopharmaceutical sector. The milestone payments from Telix reflect the mutual commitment to advancing the availability of Ac-225 for clinical applications.
Telix Pharmaceuticals, known for its expertise in developing radiopharmaceutical therapies, stands to benefit from a steady supply of Ac-225, which will enable the company to accelerate its clinical programs. Together, the two companies aim to overcome supply chain bottlenecks, ensuring that Ac-225 is accessible for both current and future therapeutic needs.
Looking Ahead
As the radiopharmaceutical industry continues to expand, collaborations like this are critical to addressing global healthcare challenges. The partnership between Eckert & Ziegler and Telix Pharmaceuticals is poised to have a significant impact on cancer treatment by improving the availability of life-saving isotopes like Ac-225.
With production scaling up and clinical applications broadening, this collaboration underscores the growing importance of radiopharmaceuticals in precision medicine. Both companies are expected to play a pivotal role in shaping the future of cancer therapy.
<a href=”https://medical.ezag.com/en/news/eckert-ziegler-and-telix-pharmaceuticals-enter-into-a-collaboration-and-license-agreement-for-actinium-225/”>Source
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
